To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Liver Cancer

Jason M. Broderick
Stivarga was granted a priority review by the FDA to treat certain patients with liver cancer in the second line setting. 
Laura Panjwani
Stivarga is being considered by the FDA for approval for second-line liver cancer treatment, renewing hope in the field. 
Virginia Powers, PhD
After doing well in a phase 3 trial, Stivarga showed the potential to shift the treatment paradigm for previously treated liver cancer.
Greg Kennelty
Michael Choti talks about what kind of advances can be expected in treating liver cancer, including PD-1 inhibitors and neoadjuvant treatment.
Suzanne Lindley
The number 18 holds special meaning for me as it marks 18 years since I heard these words: “You have incurable colon cancer.”
Andrew J. Roth
Morris Sherman discusses finding second-line treatments for patients with HCC. 
Andrew J. Roth
The incidence of NASH-associated liver cancer is growing, prompting researchers to further investigate this subset of patients.
Andrew J. Roth
CURE spoke with Ghassan K. Abou-Alfa about the potential of using a vaccinia to treat advanced HCC.
Brielle Urciuoli
After more than two decades, the International Agency for Research on Cancer re-evaluated the carcinogenic of coffee, and looked to the beverage temperature instead. 
Jason M. Broderick
Stivarga (regorafenib) proved to have better overall survival for patients with HCC in a recent phase 3 trial. 

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other